Valor202020212022202320242025TTMGastos comerciales, generales y administrativos10.47 B9.63 B10.04 B10.5 B10.82 B10.73 B10.73 BInvestigación y desarrollo13.56 B12.24 B13.55 B30.53 B17.94 B15.79 B15.79 BBeneficio operativo4.29 B10.64 B14.1 B-437 M17.47 B18.36 B17.74 BTotal de ingresos no operativos1.14 B2.69 B-2.3 B27 M845 M484 M484 MGastos por intereses, netos de intereses capitalizados831 M806 M962 M1.15 B1.27 B1.36 B1.36 BIngresos no operativos, una vez deducidos los gastos por intereses-578 M545 M-1.76 B-653 M-450 M-722 M-722 MIngresos/gastos extraordinarios886 M1.34 B-1.5 B-466 M24 M-151 M-151 MBeneficio antes de impuestos8.79 B13.88 B16.44 B1.89 B19.94 B21.07 B21.07 BParticipación en los beneficios———————Impuestos1.71 B1.52 B1.92 B1.51 B2.8 B2.8 B2.8 BParticipación minoritaria15 M16 M7 M12 M16 M9 M9 MOtros ingresos/gastos después de impuestos49 M-805 M-1.3 B-355 M-510 M-511 M-511 MBeneficio neto antes de actividades interrumpidas7.07 B12.34 B13.81 B-342 M17.12 B18.25 B18.25 BOperaciones suspendidas—707 M707 M707 M———Beneficio neto7.07 B13.05 B14.52 B365 M17.12 B18.25 B18.25 BAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas7.07 B13.05 B14.52 B365 M17.12 B18.25 B18.25 BBeneficio básico por acción2.795.165.730.146.767.37.3Beneficio por acción diluido2.785.145.710.146.747.287.28Número medio de acciones ordinarias2.53 B2.53 B2.53 B2.54 B2.53 B2.5 B10.03 BAcciones diluidas2.54 B2.54 B2.54 B2.55 B2.54 B2.51 B10.05 BEBITDA7.91 B13.85 B18 B3.44 B21.97 B24.2 B23.58 BEBIT4.29 B10.64 B14.1 B-437 M17.47 B18.36 B17.74 BCosto de los ingresos15.48 B13.63 B17.41 B16.13 B15.19 B16.38 B16.38 BOtros costes de producción———————Amortización y depreciación (flujo de caja)3.63 B3.21 B3.91 B3.87 B4.5 B5.84 B5.84 B
Merck & Company Inc (new)
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue.
The company's revenues are primarily from cancer treatments, vaccines, and animal health products. In 2024, 46% of the company's revenue, or $29.5 billion, came from sales of Keytruda, a PD-1 inhibitor used to treat various types of cancers, and 13% of the company's revenue, or $8.6 billion, came from sales of Gardasil, an HPV vaccine. In addition, 9% of the company's revenue, or $5.8 billion, came from the sales of animal health products.
The company is ranked 65th on the Fortune 500 and 76th on the Forbes Global 2000.
In 1891, Merck & Co. was established as the American affiliate of Merck Group, founded by the Merck family, and the companies are still in trademark disputes in several countries over the right to use the name "Merck".